Lundbeck Leans On Licensing To Overcome Lexapro/Cipralex Expiry
As lead drug Lexapro/Cipralex faces genericization, Lundbeck is counting on revenues from ongoing licensing deals to fill the $1 billion hole.
As lead drug Lexapro/Cipralex faces genericization, Lundbeck is counting on revenues from ongoing licensing deals to fill the $1 billion hole.